AI Health & Biotechnology
Lilly, METiS strike AI drug-delivery deal worth up to $1.1B
The collaboration will use METiS’s AI platform to develop lipid nanoparticles designed for tissue-specific delivery.
Illustration of lipid nanoparticles carrying therapeutic molecules toward different tissue cells, with an abstract pattern suggesting computational design.
Photo: Kronos News
Eli Lilly and METiS TechBio have agreed to collaborate on lipid nanoparticle (LNP) delivery technologies, with METiS eligible for up to approximately $1.1 billion in development, regulatory and commercial milestone payments, plus tiered royalties. METiS said the agreement also includes an upfront payment in the low double-digit millions of U.S. dollars. [1]
The companies plan to use METiS’s AiLNP platform to discover and optimize ionizable lipids, while Lilly contributes drug discovery, development and commercialization expertise, according to METiS’s October 19, 2026 announcement. [1] The company says the research aims to improve tissue targeting and distribution; the announcement does not report results demonstrating that the approach works in medicines or patients. [1]
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
The announcement is from METiS, a party to the collaboration, and no independent source or research results are provided.
Sources
Related stories
View all
Topics
About the author
Kronos News Desk covers ai health & biotechnology and editorial analysis for Kronos News.